[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444418":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":7,"responsibleParty":21,"collaborators":7,"id":23,"slug":7,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":27,"acronym":7,"eligibilityCriteria":28,"healthyVolunteers":24,"sex":29,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":30,"phases":7,"briefSummary":31,"conditions":32,"keywords":34,"overallStatus":41,"whyStopped":7,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":46,"locationsCount":7},{"fullName":5,"class":6},"Ridgeback Biotherapeutics, LP","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Ansuvimab","single infusion 50 mg\u002Fkg IV",[14],"mAb114, Ebanga",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Sabue Mulangu, MD,DTMH,PhD","CONTACT","+1 786 687 24951","EAP-requests@ridgebackbio.com",{"type":22,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100444418",false,"NCT05067166","Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP","Open-Label, Expanded Access Protocol of a Human Monoclonal Antibody, Ansuvimab (mAb114), Administered As a Therapeutic to Ebola-Infected Patients or As a High-Risk Ebola Post-Exposure Prophylaxis","Inclusion Criteria:\n\n* Male or female with laboratory confirmed (based on local standard of care) EBOV infection or with recent high-risk EBOV exposure as determined by a treating Physician or designee.\n* Able to provide proof of identity to the satisfaction of the clinical team\n* Able and willing to complete the informed consent process personally, or if the patient is unable to do so, then informed consent completed by a legally-authorized representative according to local laws and regulations.\n\nExclusion Criteria:\n\n\\- Any medical condition that, in the opinion of the Treating Physician, would place the patient at an unreasonably increased risk through participation in this treatment protocol.","ALL","EXPANDED_ACCESS","The human monoclonal antibody (mAb), ansuvimab (mAb114), will be provided to Ebola-infected patients as either a treatment or as PEP under an expanded access protocol. Ansuvimab is administered at 50 mg\u002Fkg as a single intravenous (IV) infusion",[33],"Ebola Virus Disease",[35,36,37,38,39,40],"EBANGA","orthoebolavirus zairense, EBOV","ansuvimab","Zaire ebolavirus, EVD","Compassionate Use","Ebola","AVAILABLE","2024-12-12",{"date":44,"type":45},"2024-12-17","ACTUAL",{"name":5,"class":6}]